Maurie Stang
Founder & Executive Chairman
Mr. Stang is the founder of iPrime Biosciences and its executive Chairman. Mr. Stang is also the founder of a number of other successful companies internationally, in the healthcare and technology sectors. These companies span, biotechnology, medical devices and a number of innovations in the “clean-tech” sector. He is currently the Chairman of Nanosonics Limited (ASX:NAN) and Aeris Environmental Limited (ASX:AEI), which are both listed on the Australian Securities Exchange. In addition, he is a founder and director of Henry Schein Halas, a joint venture with the NASDAQ-listed Henry Schein, Inc.
Mr. Stang has also established a number of prominent private companies covering research and development, large scale healthcare distribution and several other highly innovative businesses. These companies have gained market leadership in their respective fields and many have won significant innovation and export awards together with strategic partnerships and licensing agreements with some of the world’s leading companies including GE, 3M, Johnson and Johnson, Getinge and Ecolabs.
Mr. Stang’s business activities and experience span the commercialization of intellectual property across global markets. He has a track record of launching and commercializing a broad range of medical and dental devices. Mr. Stang is also a Principal of Gryphon Capital Pty Limited, an independent investment house that facilitates the financing and development of emerging health-care related entities.
Dr Yann Gambin
Founder & Technical Director
Dr Gambin is a Technical Director of iPrime Biosciences. Dr Yann Gambin is a Senior Lecturer at UNSW, and an EMBL Australia group Leader.
After a PhD in biophysics in Paris, he went on for a first postdoc at the Scripps Research Institute in San Diego. In 2010, he transitioned to a semi-independent position at the University of Queensland, under a Queen Elizabeth II fellowship. After an ARC Future Fellowship (2012-2017), he joined the EMBL Australia network, supported by ARC and NHMRC grants.
Dr Gambin has developed new single-molecule techniques to probe protein oligomerisation and protein-protein interactions, and applied these techniques to the detection of pathogens at the single molecule level. He has also been applying these techniques to probe key questions relating to cell biolog, particularly studying the self-association mechanisms that drive signalling in innate immunity. His recent outputs in terms of publications (11 publications in 2018, 3x Nature Communications in 2019), citations (> 250 cites/year) and invited contributions testify to a strong national and international standing.
In the last 5 years as an independent group leader at the University of New South Wales, he has developed an extensive library of human proteins, covering all pathways of innate immunity. His group uses state-of-the-art single molecule spectroscopy and imaging techniques, combined with high-efficiency cell-free expression system produced in house. He has now refocused his laboratory on studying the interference of viral proteins on these innate immune pathways, with two key projects focusing on SARS-CoV-2 and Nipah viruses.
Dr Emma Sierecki
Founder & Technical Director
Emma Sierecki is another Technical Director of iPrime Biosciences.
Ms Sierecki is a Senior Lecturer at UNSW and leads an independent group in the EMBL-Australia node in Single Molecule Science. She received a PhD in Chemistry from University Rene Descartes-Paris 5 in 2005. She then moved to a postdoctoral position at University of California San Diego (UCSD, USA) where she worked under the supervision of Pr. A. Newton on the biochemical characterization and drug discovery on PHLPP, a phosphatase that deactivates Akt and PKC. She then moved to Australia and worked as a postdoctoral fellow at the institute of Molecular biology (IMB, UQ) in Pr. Alexandrov’s laboratory where she studied PPI from cell-free expressed proteins.
Ms Sierecki then moved to UNSW and started her group in 2015 focusing on the biochemical and biophysical characterization of PPI and protein self-assembly. This PPI interrogation platform has been applied to different areas of biology where knowledge is currently limited by difficult access to proteins. A particular interest in her laboratory is the biophysical studies of PPIs involved in transcriptional regulation and small molecules that are capable of modulating these mechanisms (SCDB 2020, IJMS 2020, eLife 2019, NAR 2018, MAbs 2018, eLife 2017,Cell Chem.Bio 2017). Her group also work to disseminate single-molecule techniques to a broader community, developing both analysis (JCB 2018, JMB2018, Sci Rep 2016, IJMS 2016) and hardware (Nat. Comm 2019). She had a provisional patent at UCSD and a current PCT at UNSW.
Dr Ivan Rajkovic
Intellectual Property Consultant
Dr Ivan Rajkovic has joined iPrime as an Intellectual Property Consultant. Dr Rajkovic joined the patent attorney profession in 1993, after a 17-year career in biomedical research, in both academic and commercial settings. He was a partner in a major Sydney-based intellectual property firm for 14 years, until his retirement from the firm in 2014.
Dr Rajkovic currently advises companies in the life sciences field on patent portfolio structuring, patent filing strategies and portfolio management.
Dr Rajkovic’s career in biomedical research comprised over thirteen years post-doctoral academic research and a further four years of commercial research and development in the field of genetic engineering and bio-pharmaceuticals. His particular technical expertise lies in the areas of molecular immunology and oncology, biomolecular engineering, transgenics, gene therapy, microbial biochemistry, diagnostics and pharmaceuticals. Dr Rajkovic is the author of 45 publications in peer-reviewed scientific journals and books in the fields of molecular and cellular biology and immunology.
As a registered patent attorney, Dr Rajkovic has extensive experience in the intellectual property field, including drafting patent specifications, patent prosecution, oppositions and litigation support,intellectual property management and the commercialisation of intellectual property. He is a frequent speaker at national and international conferences in the field of biotechnology patenting, commercialisation and IP management.
Daniel Stang
Commercial Manager
Daniel Stang is a Director and the Commercial Manager of iPrime Biosciences. Mr Stang graduated from the University of Sydney with a Commerce-Science double degree in 2016, majoring in Finance and Biology.
During his career to date, Mr Stang had a short time at CHAMP Ventures, one of Australia’s leading Venture Capital firms before acquiring management experience in the Healthcare vertical of Zip Co. Ltd (ASX:ZML). At Vectus Biosystems (ASX:VBS) he gained experience in both drug synthesis and the development of next-generation Accugen for qPCR. He has a continuing role as a Biotech Analyst at Gryphon Capital, covering some of Australia’s leading Biotech and Medtech companies.
Linda Walters
